Israel Englander Cel Sci Corp Transaction History

Millennium Management LLC

$199 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.11 - $1.85 $21,136 - $35,227	-19,042 Reduced 27.33%	50,636 $58,000
Q1 2024 May 15, 2024	BUY	$1.63 - $3.08 $113,575 - $214,608	69,678 New	69,678 $133,000
Q2 2023 Aug 14, 2023	SELL	$2.11 - $2.83 $102,982 - $138,123	-48,807 Reduced 42.24%	66,743 $160,000
Q1 2023 May 15, 2023	SELL	$2.17 - $3.13 $216,223 - $311,879	-99,642 Reduced 46.3%	115,550 $268,000
Q4 2022 Feb 14, 2023	SELL	$1.99 - $3.52 $143,488 - $253,809	-72,105 Reduced 25.1%	215,192 $506,000
Q3 2022 Nov 14, 2022	SELL	$3.09 - $5.23 $881,895 - $1.49 Million	-285,403 Reduced 49.83%	287,297 $888,000
Q2 2022 Aug 15, 2022	BUY	$2.58 - $4.99 $1 Million - $1.94 Million	389,513 Added 212.63%	572,700 $2.58 Million
Q1 2022 May 16, 2022	BUY	$3.93 - $7.7 $83,115 - $162,847	21,149 Added 13.05%	183,187 $720,000
Q4 2021 Feb 14, 2022	BUY	$7.1 - $12.82 $964,719 - $1.74 Million	135,876 Added 519.36%	162,038 $1.15 Million
Q3 2021 Nov 15, 2021	SELL	$7.64 - $12.49 $17,755 - $29,026	-2,324 Reduced 8.16%	26,162 $288,000
Q2 2021 Aug 16, 2021	BUY	$8.68 - $27.49 $146,058 - $462,574	16,827 Added 144.33%	28,486 $247,000
Q1 2021 May 17, 2021	BUY	$12.0 - $27.64 $139,908 - $322,254	11,659 New	11,659 $177,000
Q4 2020 Feb 16, 2021	SELL	$11.05 - $16.62 $175,838 - $264,474	-15,913 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$11.69 - $14.54 $70,969 - $88,272	-6,071 Reduced 27.62%	15,913 $203,000
Q2 2020 Aug 14, 2020	SELL	$9.75 - $17.6 $31,200 - $56,320	-3,200 Reduced 12.71%	21,984 $328,000
Q1 2020 May 14, 2020	BUY	$7.54 - $17.05 $94,325 - $213,295	12,510 Added 98.71%	25,184 $291,000
Q4 2019 Feb 14, 2020	BUY	$6.71 - $9.55 $85,042 - $121,036	12,674 New	12,674 $116,000

Others Institutions Holding CVM

# of Institutions

Shares Held

Call Options Held

27.1K

Put Options Held

150K

View Full List

About CEL SCI CORP

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

More about CVM

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account